![]() Brady Brammer (R), passed the House Health and Human Services Committee in a 10-1 vote. The latest breakthrough occurred last week, when a Utah House committee approved a bill that would create a task force to study and make recommendations on the therapeutic potential of psychedelic drugs and possible regulations for their lawful use. A plethora of state legislatures have either passed bills, gone to committee with prospective bills, or are initiating debate for state-sanctioned research initiatives. The suboptimal performance in psychedelic stocks over the past year belies a rapidly improving regulatory picture as it pertains to sector research. With established partnerships with Mycrodose Therapeutics, Mycotopia Therapies, Cube Psytech, Allied Health, ATMA Journey Centers and Revive Therapeutics, distribution channels are in place and ready to scale.Īn Improving Regulatory Outlook On Psychedelic Research It also validates the company’s supply chain business model of providing psilocybin for clinical use and research. The agreement with Nectar paves the way for subsequent exportation of naturally derived psilocybin from Jamaica. In late November 2021, Havn announced it had successfully exported naturally-derived psilocybin from its facility in Jamaica to Nectar Health Sciences Laboratory Division-a Controlled Substance Dealer’s License holder for the relevant psychedelic compounds issued by Health Canada. And it has done so as recently as Q4 of 2021. While a Dealer Licence has not yet been obtained by the company, it can import psilocybe mushrooms to various partners that carry such a designation. Unlike its natural health product segment, the aim is to provide psychedelic extraction and supply both academic researchers and microdosing therapies in pre-clinical settings. A successful application would allow them to permit sale of proprietary formulations to third-party research organizations. Havn Labs has applied to Health Canada for a Dealer’s Licence provision to the Food and Drugs Act of Canada for standardized psychoactive compounds. Its mission: to develop a compound library designed to support the science of safe, quality-controlled psychoactive compounds for the research community. Through its HAVN Labs division, the company is engaged in the development of research protocols to cover the production of psilocybe mushrooms, research, extraction, formulation, delivery and standardization of industry-based medicines. This is being accomplished through a subsidiary that focuses on capitalizing on the complete lifecycle of the compound. Using evidence-informed research, Havn Life Sciences is committed to helping clinical researchers to unlock the potential of fungi-based medicine in a traditional pharmaceutical setting. Havn Life Sciences Is More Than Functional Mushroom SupplementsĪlthough its pending acquisition is getting a lot of focus from investors, the company is more than just a natural supplement retailer. There are no surprises or miscalculations with this deal-only adherence to an end goal of capturing as much market share as possible. With Spore selling products with inherent consumer staples properties, revenues are expected to be stable and predictable relative to pure-play consumer discretionary retail models.Īs noted, Havn Life Sciences already maintains their own line of functional mushroom supplements, therefore the Spore acquisition should be highly synergistic with their existing business model. Many of these patrons prioritize personal wellness through the use of supplementation, and are thus repeat customers. The Toronto-based company is a leading wellness brand in the emerging functional mushroom arena, which boasts more than 110,000 customers and nearly 40,000 subscribers. Perhaps somewhat obscured by the approaching holiday season, the definitive agreement to acquire Spore Life Sciences was a significant one. With its recent definitive agreement to acquire Spore Life Sciences, Havn will acquire a business with significant recurring revenue and even positive cash flow, based on November 2021 sales. Havn Life Sciences ( CNSX: HAVN) ( OTCMKTS: HAVLF)-a biotechnology company pursuing standardized extraction of psychedelic compounds and sales of natural health products-is breaking the mold. But not every sector company is tethered to this dastardly fate. Although the psychedelics industry has a great future ahead of it, meaningful revenue production is generally limited in the near term.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |